Jim Glazen

Dendreon Jumps on New Cancer Vaccine Report

Dendreon's trials failed to statistically slow tumor progression but also were not designed to measure survival as an endpoint. I fail to see how a change in FDA requirements for approving cancer vaccines would help Provenge gain approval sooner than thought.

Dendreon needs to complete the current trial which is not even fully enrolled yet.

Dendreon "investors" are about the dumbest of the dumb in my opinion. They ran the stock up to $11 per share on news that the FDA wanted Dendreon to complete the current trial only to watch the stock settle back down to $6.50.

In my opinion, Mitch Gold, CEO told you all you needed to know just days after the FDA panel. He dumped 200,000 shares at $13+. Anyone with half a brain should have followed him out the door and never look back.

I frankly believe that Provenge does add some benefit. It's definitely not a cure and might add 4 months of survival. $60,000 cancer treatments for 4 extra months of life is the reason our health care costs are skyrocketing. We need more research dollars devoted to prevention and healthy lifestyle habits.